ACPE/CE-Certified Webcast:Role of the Pharmacist and CGM Technology in Intensive Treatment of Diabeteswith Sam Ellis, PharmD, BCPS, CDE
To receive CE credit, please Register, take the Pretest below, view the Webcast, successfully pass the Posttest and complete the Evaluation.
Sam Ellis, PharmD, BCPS, CDE
Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado
Pharmacists, primary care physicians, nurse practitioners, certified diabetes educators, endocrinologists, and other healthcare professionals interested in the management of diabetes.
Statement of Need
Self-monitoring of blood glucose is a core component of a diabetic patient's management but only provides a measurement of blood glucose levels at a specific point in time, without necessarily informing about trends and hyperglycemic or hypoglycemic excursions. Glycosylated hemoglobin (A1C) is an even more limited measure, as it reports a mean of readings over 90 days; therefore, the patient is not alerted about fluctuations in blood glucose at any point in time.
Selection of an appropriate continuous glucose monitoring (CGM) device is important because improvements in accuracy and reliability are ongoing. Real-time (RT) CGM is one cornerstone of optimal glycemic control. Each CGM device varies; relying on different sensing technology and requiring the traditional finger-sticks for confirmation of alerts. The mean absolute relative difference (MARD) between sensor readings and reference glucose levels can vary by as much as 20%, with worrisome discrepancies in the hypoglycemic range. However, new-generation devices have significantly improved MARD measurements. These devices have shorter lag times and greater accuracy.
Many physicians are lacking the appropriate level of knowledge to employ CGM in their practices. Educational programs focused on these knowledge gaps will enable healthcare professionals to provide improved patient care.
At the conclusion of this activity, participants should be better able to:
- Understand how patients living with Type 1 diabetes use their continuous glucose monitoring (CGM) device to make management decisions
- Identify methods for optimization of therapy and improve clinical outcomes using real-time (RT) personal and professional CGM in both adult and pediatric populations
- Recognize the role of pharmacists in communicating about CGM and providing patient education to improve CGM device selection and optimize adherence
Accreditation and Certification
CPE Consultants, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). The Universal Activity Number (UAN) for this activity is 0864-0000-16-056-H04. The activity is accredited for 0.5 contact hours (0.05 CEUs). The official release date for this activity is July 8, 2016 and the expiration date is July 8, 2017.
There is no registration fee for this activity
Requirements for CE Credit
Upon completion of the requirements for this activity (completing the pretest, viewing the webcast and successfully passing the posttest), a statement of credit is generated from the approved provider, CPE Consultants, LLC.
Your continuing education credits will be electronically be uploaded to CPE Monitor within 48 hours. Please check your CPE Monitor account to make sure your credits were accurately reported. We encourage participants to keep a printed copy of all statements of continuing education credit.
Disclosure Policy Statement
It is the policy of CPE Consultants LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. CPE Consultants LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
CPE Consultants, LLC Disclosure
Anne Hermiller and John Stanovich, RPh have no real or apparent conflicts of interest to report.
CogniMed Inc Staff
Jeffrey Rosenberg, Project Coordinator, has nothing to disclose.
Sam Ellis, PharmD, BCPS, CDE, has nothing to disclose.
This activity is supported by independent educational grants provided by Dexcom.
This activity is an enduring material and consists of an audio recording and slide presentation or a written manuscript with graphics. Successful completion is achieved by listening to the audio and viewing the slide presentation or reading the manuscript with graphics, reflecting on the content's implications in your practice, and completing the assessment component.
The estimated time to complete this activity is 0.50 hour.
To receive credit for this activity, participants must complete the posttest with a passing score of 80% and then complete the evaluation.
This activity was originally released January 9, 2015, and is eligible for credit through July 8, 2016.
This activity was reviewed by an impartial content reviewer and by faculty. Faculty have final editorial control over the piece.
ACPE/CE Registration and Pretest
Please enter your email address below and then provide any additional missing required information. The pretest is below.
1. What percent of patients are on insulin-containing regimens?
2. Per the American Diabetes Association Standards of Care, continuous glucose monitoring (CGM) has ______evidence supporting its use than self-monitoring of blood glucose for reducing A1c values?
3. A study evaluating differences between CGM devices published in Diabetes Technology & Therapeutics emphasized the importance of?
4. How does CGM help overcome barriers contributing to clinical inertia?
5. With CGM, what is the role of the pharmacist?
Thank you for registering. You will, or may have already received, the links for this webcast in a confirmation email. Please contact us if you have any questions.
© 2014 CogniMed Inc. All rights reserved. CGM16002 July 2016